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Objective: Although physical therapy can help preserve mobility in patients with sys-
temic sclerosis (SSc), stretching has not been used systematically as a treatment to 
prevent or reverse the disease process. We previously showed in rodent models that 
stretching promotes the resolution of connective tissue inflammation and reduces new 
collagen formation after injury. Here, we tested the hypothesis that stretching would 
impact scleroderma development using a mouse sclerodermatous graft-versus-host 
disease (sclGvHD) model.
Methods: The model consists in the adoptive transfer (allogeneic) of splenocytes from 
B10.D2 mice (graft) into Rag2−/− BALB/c hosts (sclGvHD), resulting in skin inflammation 
followed by fibrosis over 4  weeks. SclGvHD mice and controls were randomized to 
stretching in vivo for 10 min daily versus no stretching.
results: Weekly ultrasound measurements of skin thickness and subcutaneous 
tissue mobility in the back (relative tissue displacement during passive trunk motion) 
successfully captured the different phases of the sclGvHD model. Stretching reduced 
skin thickness and increased subcutaneous tissue mobility compared to no stretching 
at week 3. Stretching also reduced the expression of CCL2 and ADAM8 in the skin at 
week 4, which are two genes known to be upregulated in both murine sclGvHD and the 
inflammatory subset of human SSc. However, there was no evidence that stretching 
attenuated inflammation at week 2.
conclusion: Daily stretching for 10  min can improve skin thickness and mobility in 
the absence of any other treatment in the sclGvHD murine model. These pre-clinical 
results suggest that a systematic investigation of stretching as a therapeutic modality is 
warranted in patients with SSc.
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inTrODUcTiOn
Systemic sclerosis (SSc, also known as scleroderma) is an autoim-
mune disorder characterized by chronic dysregulation of innate 
and adaptive immune systems, vasculopathy, and fibroblast dys-
function resulting in fibrosis (1). Although clinical manifestations 
of SSc are heterogeneous, their hallmark is skin fibrosis, including 
the dermis and subcutaneous tissue (1–3). When subcutaneous 
tissue becomes fibrotic, adhesions can form between the skin and 
underlying connective tissues, which leads to impaired move-
ment between these tissue layers and decreased range of motion 
(4). Non-pharmacological treatments, including physical therapy 
and stretching, are thought to be important adjuncts to pharma-
cological treatment in patients with SSc (5). However, there is 
evidence that these types of interventions are underutilized, and 
stretching has not been used systematically to prevent or reverse 
the diseases process (6, 7). Conversely, the possibility that lack of 
movement may itself be an important contributor to the patho-
physiology of the disease has not been investigated. Thus, the lack 
of a standardized approach to stretching, including the correct 
“dose,” and dearth of insight into the mechanisms engaged at 
the tissue level by stretching has limited the application of this 
potentially powerful, yet non-invasive treatment (7–9).
We have previously developed an animal model in which 
mice or rats spontaneously stretch their whole body when they 
are partially lifted by the tail and allowed to grasp the edge of a 
surface with their front paws (10). When held in this position, the 
animals spontaneously extend both front and hind limbs, which 
increases the distance between shoulders and hips by ~25%. Using 
this model, we showed that stretching promotes the resolution of 
inflammation in subcutaneous connective tissues of the back and 
decreases newly formed collagen in a subcutaneous connective 
tissue injury model (10–12).
Because inflammation and fibrosis are known to contribute to 
the development of SSc pathology, the goal of this study was to 
test the effect of daily stretching in a murine model of SSc. The 
mouse sclerodermatous Graft-versus-host disease (sclGvHD) 
has been demonstrated to mimic a subset of SSc patients with 
an inflammatory gene signature (13, 14). In this model Rag2−/− 
BALB/c hosts (sclGvHD mice) receive adoptively transferred 
splenocytes from MHC-matched allogeneic B10.D2 mice (graft). 
The graft-versus-host reaction culminates in skin inflammation 
and fibrosis. Seven days after splenocyte transfer, the sclGvHD 
mice lose weight and inflammatory cells begin to infiltrate the 
skin. Over the course of the following 4 weeks, collagen accumu-
lates in the skin and fibrosis is clinically manifested as alopecia 
(15) (15–17). We used novel high-frequency ultrasound methods 
to follow the course of the disease and measure the impact of 
stretching. Our ultrasound measures included the thickness 
of skin and subcutaneous tissue, as well as the relative motion 
between the skin and underlying subcutaneous connective tissue 
layers in dynamic ultrasound recordings during passive flexion 
of the trunk. We chose to focus our measurements on the skin 
and subcutaneous tissues of the back, which provide accessible 
flat tissue planes that can be measured reliably with both static 
and dynamic imaging as previously demonstrated in humans 
and large animals (18–20), and used high-frequency (50 MHz) 
ultrasound, which provides the high resolution needed to 
apply these techniques to rodents. We hypothesized that, in the 
absence of stretch, ultrasound measurement of skin thickness are 
increased and subcutaneous tissue mobility are decreased in sclG-
vHD compared with control mice. We further hypothesized that 
stretching attenuates these abnormalities in the sclGvHD mice. 
In addition, because sclGvHD demonstrates a gene expression 
pattern similar to the inflammatory subset of scleroderma (13, 
14) and increased expression of extracellular matrix-associated 
pathways is evident in this inflammatory subset (13), we also 
examined the expressions of TGF-β, TIMP1, MMP-12, ADAM8, 
IL4RA, and CCL2 genes which have been previously shown to 
be upregulated in both murine sclGvHD and the inflammatory 
subset of SSc patients (13, 14, 21, 22).
MaTerials anD MeThODs
Mice and sclgvhD Model
The animal testing protocol used in this study was approved by 
the Harvard Medical School Institutional Animal Care and Use 
Committee. Rag2−/− mice on a BALB/c genetic background were 
generated as described previously in Ref. (13, 23). BALB/c and 
B10.D2, mice were obtained from the Jackson Laboratory (Bar 
Harbor, ME, USA). All mice were housed in a specific pathogen-
free animal facility at the Harvard School of Public Health. Mice 
were housed and maintained in accordance with the Guide for 
Care and Use of Laboratory Animals. The drinking water of 
all Rag2−/− mice was supplemented with sulfamethoxazole and 
trimethoprim (Sulfatrim, Hi-Tech Pharmacal, 0.6 mg/ml drink-
ing solution). The sclGvHD model was established as described 
previously (15).
Six- to nine-week-old males were used for all the experiments. 
Briefly, 20–40 million BALB/c (syngeneic) or B10.D2 (allogeneic) 
red-blood-cell-free splenocytes were transferred via tail-vein 
injection into host mice. Injection of allogeneic splenocytes 
produced the sclGvHD phenotype, while injection of syngeneic 
splenocytes served as controls. The mice were weighed and 
scored clinically once a week by a blinded observer as follows: 
0 = no evidence of disease, 1 = fur ruffling or hunched posture, 
2 = alopecia < 25% of body surface area, 3 = alopecia > 25% of 
body surface area, and 4 = death or a veterinary order to eutha-
nize. Half a point was added for periorbital swelling.
study Design
Mice were randomized into one of four groups (N = 12/group): 
syngeneic control/no stretch (Ctl-NS), syngeneic control/stretch 
(Ctl-S), sclGvHD/no stretch (Scl-NS), and sclGvHD/stretch 
(Scl-S). Allogeneic (sclGvHD) or Syngeneic (Control) spleno-
cytes were injected on day 0. The control group was included 
to document the effect of scleroderma using ultrasound. The 
stretch (or no stretch) interventions were performed for 10 min 
once a day, 5 days per week, for 4 weeks, beginning 3 days after 
splenocyte injection. Ultrasound measurements were performed 
once a week during the 4-week intervention, except at week 0 
due to barrier facility constraints. At all time points, ultrasound 
measurements were taken 1  h after the last stretching (or no 
FigUre 1 | Ultrasound imaging acquisition and stretching methods. 
(a,B): Stretching (a) and no stretching (B) interventions. (c): Location of 
rostral and caudal levels for acquisition of transverse ultrasound images.  
(D): Position of mouse on articulated table during acquisition of dynamic 
ultrasound imaging during upward and downward table motion. (e): Angle of 
table motion.
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stretching) session. At the end of week 4, mice were euthanized 
by decapitation under deep isoflurane anesthesia immediately 
after the last ultrasound measurements, and skin samples from 
the back were excised for histology and gene expression analysis 
after shaving the back.
intervention Methods
Stretching method: mice were stretched by gently lifting them by 
the base of the tail until reaching ~45° angle to the horizontal. 
While grasping onto a bar with their front paws, the mice spon-
taneously extend their hind limbs. The stretching, which exerted 
traction on the whole back, increases the distance between the 
shoulder and hip by ~25% (10). With minimal habituating, mice 
were able to hold this position comfortably for 10 min without 
struggling, vocalizing, or other signs of distress (Figure 1A). No 
stretching (sham): mice were removed from their cage for 10 min 
but were neither lifted nor stretched (Figure 1B).
Ultrasound Data acquisition
All ultrasound data acquisition and measurements were 
performed by investigators blinded to intervention condition. 
Ultrasound images of the back were acquired under isoflurane 
anesthesia. A high-frequency ultrasound scanner (Vevo 2100, 
Fujifilm VisualSonic, Toronto, ON, Canada) in B mode with 
a 50-MHz transducer (MS 700) was used for optimal spatial 
resolution, which provided a resolution of 30  µm  ×  75  µm 
(axial × lateral) and a focal length of 5.0 mm. A conductive gel 
was centrifuged for 5  min to remove air bubbles and spread 
over the skin. To ensure complete contact between the skin and 
the transducer, the fur in the back of the mice was parted after 
applying the gel and prior to imaging. This was done rather than 
shaving to avoid injury or irritation to the skin. The transducer 
was stabilized with a clamp and mounted into an articulated arm 
to control the distance and the angle between the transducer and 
the skin surface. For skin thickness measurements, the transducer 
was oriented transversely, perpendicular to the skin of the back 
and centered on the midline. Ultrasound images were acquired at 
two levels, one rostral and one caudal, on the left side of the back 
as shown in Figure 1C. For cumulative displacement measure-
ment, the transducer was oriented longitudinally, 0.5 cm lateral 
and parallel to the midline and centered on the caudal level. 
Accurate positioning was achieved by regulating the micrometric 
screws and great care was taken to position the transducer in 
such a way as to avoid any compression of the skin (Figure 1D). 
In each mouse, an ultrasound cine-recording was acquired on 
the right and left sides of the back during cyclical passive trunk 
flexion using an articulated table with the hinge point of the table 
at the level of animal’s axilla. The table moved up and down at 
0.5 Hz at a 17° angle (Figure 1E) from the horizontal for a total 
of four cycles.
Ultrasound image Measurement
For measurement of skin thickness, three zones were defined 
on the ultrasound images as illustrated in Figures 2A–C: Zone 
1 (skin and subcutaneous tissue) extended from the superficial 
border of the dermis to the superficial border of the erector spinae 
muscle. Zone 2 (skin) extended from the superficial border of the 
dermis to the superficial border of the subcutaneous muscle, and 
Zone 3 from the superficial border of the subcutaneous muscle 
to the superficial border of the erector spinae muscle. Thickness 
measurements were performed at two fixed points, 1.5  mm 
(medial) and 2.5  mm (lateral) from the midline, respectively 
(Figure 2B). Thickness measurements at the four sites (upper and 
lower levels, medial, and lateral points) were averaged and taken 
as the outcome measure for Zones 1, 2, and 3 thickness.
For measurement of cumulative displacement, two segments 
were defined at the superficial border of the dermis (segment 
A) and the superficial border of the erector spinae perimuscular 
fascia (segment B), respectively (Figure 2D). Tissue displacement 
for each segment was measured using Vivovasc software as the 
tangential displacement during successive 40 ms increments over 
the two middle cycles of table motion (Figure  2E). Tangential 
displacement is defined as displacement along the direction of 
tissue planes (skin and perimuscular fascia). The absolute cumu-
lative difference between the displacement of superficial and deep 
segments was calculated and taken as the outcome measure for 
relative tissue displacement. Ultrasound image measurement 
intra-rater reliability (ICCs) were r =  0.98 for tissue thickness 
and r = 0.87 for tissue displacement.
histopathological assessment
At 4 weeks after splenocyte transfer, tissue specimens including 
skin, subcutaneous tissue, and muscle were excised from the 
FigUre 2 | Ultrasound image analysis methods. (a–c): ultrasound thickness measurements. Medial and lateral locations are, respectively, 1.5 and 2.5 mm 
from the midline (a,B). Zones 1–3 are shown in ultrasound (B) and corresponding histology (c) image shows relation to dermis, loose subcutaneous (sc) tissue, 
subcutaneous (sc) muscle, and trunk muscle (erector spinae). (D,e): Ultrasound measurement of tissue differential displacement. Segments a and b are, 
respectively, located on the superficial border of the dermis and the superficial border of the erector spinae perimuscular fascia. (e): representative tracing of 
tangential displacement of superficial and deep segments shown in (D) (segment A yellow and segment B green).
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shaved skin of one side of the back between the rib cage and 
the highest point of iliac crest, fixed in 10% neutral-buffered 
formalin, embedded in paraffin, and stained with standard hema-
toxylin and eosin (H&E). A blinded observer experienced in SSc 
pathology (Robert Lafyatis) scored H&E-stained back skin tissue 
samples per mouse for four parameters (fibrosis, inflammation, 
fat loss, and epidermal hypertrophy), using a semi-quantitative 
scale from 0 to 4. Values were summed to derive a combined 
histopathological score (13).
Quantitative real-time Pcr
For mRNA expression studies, RNA was extracted from tissue 
samples corresponding to Zone 1 (skin and subcutaneous tis-
sue) on the side contralateral to that used for histology. RNA 
was extracted using Trizol reagent (Qiagen, Santa Clarita, CA, 
USA) and reverse transcribed into cDNA with the Affinity Script 
CDNA Synthesis Kit (Agilent Technologies, Wilmington, DE, 
USA). Real-time quantitative PCR (qPCR) was performed using 
Sybr green reagent (Life Technologies, Grand Island, NY, USA). 
CT values for duplicate samples were averaged, and the amount of 
mRNA relative to a housekeeping gene transcript was calculated 
using the ΔCT method. Data were normalized to Hprt. The qPCR 
conditions were: 3 min 95°C, then 40 cycles of 10 s at 94°C, 10 s 
at 60°C, and 20  s at 72°C. Primers used for qPRC analysis are 
listed in Table 1.
Ex Vivo Tissue explant stretching 
experiments and Fibroblast Morphological 
Measurements
Two separate ex vivo experiments were performed using subcu-
taneous connective tissue explants as previously described (24). 
In the first experiment, we compared four groups of mice without 
in vivo stretching (N = 4 mice per group): control mice euthanized 
at week 2, sclGvHD mice euthanized at week 2, control mice 
euthanized at week 4, and sclGvHD mice euthanized at week 4. 
TaBle 1 | Q-Pcr primer sequence.
gene Primer forward Primer reverse
Adam8a AGTTCCTGTTTATGCCCCAAAG AAAGGTTGGCTTGACCTGCT
Ccl2b GGCTCAGCCAGATGCAGTTAA CCTACTCATTGGGATCATCTTGCT
Hprtb GTTAAGCAGTACAGCCCCAAA AGGGCATATCCAACAACAAACTT
Il4rab TCTGCATCCCGTTGTTTTGC GCACCTGTGCATCCTGAATG
Mmp12c GAACTTGCAGTCGGAGGGAA TCTTGACAAGTACCATTCAGCA
Tgfb1c CTTCAATACGTCAGACATTCGGG GTAACGCCAGGAATTGTTGCTA
Timp1a GCAACTCGGACCTGGTCATAA CGGCCCGTGATGAGAAACT
aPrimers were selected from the Primer Bank website.
bPrimers were described in Ref. (13).
cPrimers were designed with Primer Blast website tool.
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The second experiment compared two groups: sclGVDH mice 
stretched in vivo for 4 weeks versus sclGVHD mice non-stretched 
(NS) in vivo for 4 weeks. In both experiments, immediately after 
euthanasia, a 8 cm × 3 cm tissue flap containing dermis, subcu-
taneous muscle, and subcutaneous tissue was excised from the 
back of the mouse. The tissue flap was cut into two pieces (right 
and left) that were randomized to ex vivo stretch versus control 
(no stretch). Each piece was placed transversely in grips and 
immersed in HEPES-physiological saline solution, pH 7.4 at 
37°, containing (millimolars): NaCl 141.8, KCl 4.7, MgSO4 1.7, 
EDTA 0.39, CaCl2 2.8, HEPES 238.3, KH2PO4 1.2, and Glucose 
5.0. The grips and tissues were placed vertically in a tissue bath 
with the proximal grip connected to a 500 g (4.9 N) capacity 
load cell. Samples randomized to ex vivo stretch were elongated 
a rate of 1 mm/s by advancing a micrometer connected to the 
distal tissue grip to 25% strain relative to the unloaded length 
(length of the tissue laying flat but not stretched) then main-
tained at that length for the duration of the incubation. Control 
samples (randomized to ex vivo no stretch) were incubated for 
the same duration without stretch. At the end of incubation, 
the tissue was immersion-fixed in 4% paraformaldehyde for 1 h. 
After fixation, areolar subcutaneous connective tissue samples 
(each 10  mm ×  10  mm) were dissected and placed flat on a 
glass slide and stained with Texas Red conjugated phalloidin 
(4 U/ml; Molecular Probes, Eugene, OR, USA) for 40 min at 4°C 
then counterstained for 2 min with DAPI (Molecular Probes, 
Eugene, OR, USA). Samples were mounted on slides using 50% 
glycerol in PBS with 1% N-propylgallate as a mounting medium 
and overlaid with a glass coverslip. Three slides were prepared 
from each sample, with an average of 3–4 images taken from 
each slide, avoiding the edges, using a 63× immersion oil lens 
and a digital camera AxioCam MRC 5, Zeiss. Images were 
imported into the analysis software package Image J for mor-
phometric analysis. An average of 30 fibroblasts were measured 
per excised tissue sample by a blinded investigator. A cell was 
excluded if part of its cell body perimeter is outside the image. 
For each cell, the cell body perimeter was traced as defined as 
the outline of the cell’s cytoplasm projected in the plane of the 
image excluding cell processes (defined as an extension of a cell’s 
cytoplasm longer than 2 µm and less than 2 µm in width at any 
portion of its length). Fibroblast cell body cross-sectional area 
was calculated as the area delimited by the cell body perimeter 
projected onto the image plane (see Figure 8 for illustration of 
method).
statistical analysis
Repeated measures analyses of variance were performed to 
examine the effects of group, time, and their interaction. 
Dependent measures were zone-specific tissue thickness, relative 
tissue displacement, clinical score, and weights. Because group 
differences were found to be time-dependent (i.e., group × time 
interaction p <  0.05 for all outcome measures), partial F-tests 
were used to compare the four groups at each time point. If the 
partial F-test was significant, Fisher’s Protected LSD was used 
to perform pairwise comparisons among groups at each time 
point to control type I error rate experiment-wise. For analyses 
of clinical score, control animals were excluded as all values were 
scored as 0. A one-way ANOVA was used to compare the four 
groups on histopathological score and mRNA expression. For 
mRNA, analyses of variance were performed on log fold change 
values, with results presented as geometric means and associated 
SEs. In a subset of animals (N = 5), estimates of intra-rater reli-
ability were computed using on intraclass correlation coefficients 
for both tissue thickness and displacement. These estimates 
were based on variance components that were derived based on 
mixed model analyses of variance. Correlation between outcome 
variables were examined using Spearman’s correlation. Repeated 
measures ANOVAs were used to examine in  vivo and ex vivo 
stretch effects on fibroblast cross-sectional area. All statistical 
analyses were performed using SAS statistical software Version 
9.4 (SAS Institute, Cary, NC, USA). Statistical significance was 
determined based on α = 0.05.
resUlTs
clinical score, animal Weight, and 
histological score
Clinical scores initially increased from baseline to week 1, subse-
quently decreased from week 1 to week 2 and rose again at weeks 
3 and 4 (Figure 3A). This is consistent with previous studies that 
identified successive phases of skin involvement in the sclGvHD 
model, with an early predominantly inflammatory phase followed 
by fibrosis and atrophy (15–17). sclGvHD animal weights paral-
leled the clinical scores by first decreasing at week 1, rebounding 
at week 2 and decreasing again at weeks 3 and 4 compared with 
controls (Figure 3B). Mean combined histological scores at week 
4 for the Scl-NS group was 5.3 ± 0.5 which is consistent with pre-
vious reports using this model (25) (Figure 3C). Animal weights 
TaBle 2 | repeated measurements at weekly time points.
Time point  
(week)
control/no stretch
N = 12
control/stretch
N = 12
sclgvhD/no stretch
N = 12
sclgvhD/stretch
N = 12
p-Value 
(anOVa)
Thickness  
Zone 1 (μm)
1 489.14 ± 13.97a 488.06 ± 17.77a 472.77 ± 16.30ab 462.60 ± 11.35b 0.040
2 486.50 ± 9.82a 485.15 ± 14.84a 606.08 ± 14.22b 599.06 ± 15.76b <0.001
3 491.67 ± 9.27a 479.52 ± 16.30a 554.85 ± 16.26b 503.19 ± 13.50a <0.001
4 473.29 ± 17.92 476.96 ± 18.47a 463.04 ± 13.93ab 448.40 ± 16.94b 0.037
Thickness  
Zone 2 (μm)
1 327.29 ± 11.39a 345.52 ± 16.10a 327.54 ± 16.64a 320.46 ± 9.75a 0.060
2 319.10 ± 9.27a 320.38 ± 12.27a 410.23 ± 11.06b 410.75 ± 16.69b <0.001
3 319.25 ± 12.75a 324.75 ± 14.43a 395.77 ± 15.91b 355.75 ± 13.05a <0.001
4 312.06 ± 17.48a 326.40 ± 17.42a 313.35 ± 12.91a 309.46 ± 15.46a 0.120
Thickness  
Zone 3 (μm)
1 161.17 ± 6.37a 142.54 ± 5.50b 145.23 ± 2.71b 142.15 ± 4.79b 0.040
2 167.40 ± 4.46a 164.77 ± 4.20a 195.85 ± 8.38b 188.31 ± 6.27b <0.001
3 172.42 ± 7.61a 154.77 ± 3.60b 159.08 ± 4.98ab 147.44 ± 4.44b 0.011
4 161.23 ± 3.70a 150.56 ± 3.78ab 149.69 ± 5.77ab 138.94 ± 5.50b 0.037
Cumulative 
displacement (μm)
1 429.98 ± 44.92a 432.64 ± 28.59a 381.75 ± 34.95a 364.27 ± 42.33a 0.238
2 422.20 ± 52.54a 464.33 ± 29.66a 416.84 ± 37.61a 455.58 ± 49.48a 0.629
3 456.93 ± 35.99a 444.10 ± 33.98a 344.88 ± 31.90b 430.00 ± 30.34a 0.037
4 457.39 ± 33.13ab 473.83 ± 23.88a 331.28 ± 38.32c 388.45 ± 22.28bc 0.003
Clinical score 1 N/A N/A 0.88 ± 0.09b 0.88 ± 0.12b 0.961
2 N/A N/A 0.04 ± 0.04b 0.13 ± 0.09b 0.864
3 N/A N/A 1.26 ± 0.32b 1.50 ± 0.36b 0.524
4 N/A N/A 2.22 ± 0.30b 1.94 ± 0.34b 0.378
Weight (g) 1 26.40 ± 0.55a 26.10 ± 0.86a 20.30 ± 0.58b 20.17 ± 0.40b <0.001
2 26.90 ± 0.58a 26.46 ± 0.73a 24.13 ± 0.44b 24.26 ± 0.38b 0.001
3 27.06 ± 0.48a 26.22 ± 0.63a 22.83 ± 0.57b 23.30 ± 0.45b <0.001
4 27.13 ± 0.51a 26.53 ± 0.70a 21.53 ± 0.59b 22.41 ± 0.48b <0.001
Results are expressed as mean ± SE. Means for experimental conditions within each time point.
Not sharing a common letter are significantly different (p < 0.05, Fisher’s protected LSD).
FigUre 3 | clinical and histological measures. (a,B): Clinical score (a) and animal weight (B) over the course of the 4-week experiment. (c): Histological 
scores at week 4. Significant differences are shown between both sclGvHD/stretch (Scl-S) and sclGvHD/no stretch (Scl-NS) compared to both Con-S and Con-NS 
groups at week 2 (*p < 0.05). There were no significant differences between Scl-S and Scl-NS groups in any of the outcome measures (N = 12 mice per group).
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were lower in both Scl groups compared with both control groups 
at weeks 1–4. Differences in clinical scores, weight, and histologi-
cal scores between Scl-NS and Scl-S groups were not statistically 
significant (Figures 3A–C; Table 2).
Ultrasound Measurement of  
Tissue Thickness
Figure  4 shows examples of ultrasound and correspond-
ing histology images for control (Figure  4A) and sclGvHD 
(Figures  4B,C) mice illustrating the greater dermal thickness 
in the sclGvHD mice visible with both ultrasound and histol-
ogy. Ultrasound measurements of Zone 1 (combined skin and 
subcutaneous tissue), Zone 2 (skin only), and Zone 3 (subcuta-
neous tissue only), all demonstrated time-dependent differences 
between the four experimental groups (ANOVA time by group 
interaction p = 0.001) (Figure 5A; Table 2). Skin and subcutane-
ous tissue thickness peaked at week 2 in the sclGvHD mice, which 
is consistent with the presence of early inflammatory edema.
FigUre 4 | Ultrasound and histology images at week 4. Ultrasound and corresponding histology images were taken from the same location on the back (at the 
location indicated in Figure 2a). (a) Control no stretch; (B) sclerodermatous graft-versus-host disease (SclGvHD) no stretch; (c) sclGvHD-stretch. Histological 
images show increased dermal collagen density in both non-stretched and stretched sclGvHD mice.
FigUre 5 | Ultrasound measurement of tissue thickness (a) and relative tissue displacement (B) over the course of the 4-week experiment in the 
four experimental groups. (a) Significant differences (p < 0.05) are shown between both sclGvHD/stretch (Scl-S) and sclGvHD/no stretch (Scl-NS) compared to 
both Ctl-S and Ctl-NS groups at week 2 (*) and between Scl-NS and the other three groups at week 3 (#). (B) Significant differences are shown between Scl-NS 
and the other three groups at week 3 (#) and between the Scl-NS and both control groups at week 4 (¶). Scl-S and Scl-NS were not significantly different at week 4 
(N = 12 mice per group).
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Stretching had a significant effect on Zone 1 (combined skin 
and subcutaneous tissue) and Zone 2 (skin only) thickness, which 
were both reduced by 11% in the Scl-S group compared with the 
Scl-NS group at week 3 (Figure 5A; Table 2). Thus, while there 
was no difference between stretch and no stretch at the peak of 
inflammation (week 2), stretched sclGvHD mice became more 
similar to controls at week 3.
Ultrasound Measurement  
of Tissue Mobility
Ultrasound measurement of relative tissue displacement between 
skin and subcutaneous tissue during passive trunk flexion 
also showed significant differences between groups (ANOVA 
p = 0.01) (Figure 5B; Table 2). Although the interaction between 
group and time was not significant, differences between groups 
were significant at weeks 3 and 4. At week 3, relative tissue 
displacement was 26% greater in the Scl-S group compared with 
the Scl-NS group (Figure 5B; Table 2). At week 4, relative tis-
sue displacement remained greater in the Scl-S compared with 
Scl-NS, but this difference was no longer statistically significant 
(Figure 5B; Table 2). There were no significant differences between 
experimental groups in the simple displacements of either skin or 
subcutaneous tissue during the passive trunk motion, indicating 
that stretching had a specific impact on the relative inter-layer 
mobility of tissues rather than the absolute amount of tissue 
displacement. Thus, as in the thickness measurements, stretching 
improved tissue mobility such that stretched sclGvHD mice were 
more similar to controls at week 3 only.
FigUre 6 | mrna expression (qPcr) analyses. (a–F): Significance levels for sclGvHD/no stretch and sclGvHD/stretch groups are shown relative to control/no 
stretch (Ctl-NS) group (*p < 0.05, **p < 0.01, N = 12 mice per group). There were no significant differences between Ctl-NS and Ctl/stretch groups for any of the 
outcome measures. Results are presented as geometric means and associated SEs, with the y-axis reflecting log scale.
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gene expression analysis
At euthanasia (week 4), we measured markers of fibrosis (TGF-β, 
TIMP1, MMP12, ADAM8) and inflammation (IL4RA, CCL2) 
that have been previously shown to be upregulated in both sclG-
vHD and SSc patients. RNA expression was significantly greater 
in the Scl-NS compared to the Ctl-NS group for TGF-β p = 0.006, 
TIMP1 p = 0.012, MMP12 p < 0.001, ADAM8 p < 0.001, and 
CCL2 p < 0.001 (Figure 6). Stretching significantly reduced the 
expression of ADAM8 and CCL2 compared with no stretch-
ing in sclGvHD mice (p =  0.011 and p <  0.001, respectively) 
(Figures 6E,F).
In order to further investigate possible anti-inflammatory 
effects of stretching suggested by the reduction in CCL2 at week 4, 
we conducted additional experiments in which mice randomined 
to in vivo stretch versus no stretch were euthanized at the peak 
of inflammation (week 2) for measurement of CCL2 along with 
additional markers of inflammation and matrix remodeling 
(COX2, PAK2, PLA2, YAP, CTGF, Adam8, MMP12, TGF-β, IL13, 
IL13ra1, IL4ra, and TIMP1). Although all markers were elevated 
in the SclGVHD mice compared with controls, we found no 
significant differences at week 2 between stretched and NS mice 
for any of the markers, including CCL2 (data not shown). This 
suggests that the reduced skin thickness and increased mobility 
observed at week 3 was not due to an early interruption of the 
inflammatory cascade.
correlation analysis
We did not observe any significant correlation between tissue 
thickness and either histological score, clinical score, or gene 
expression measures. However, relative tissue displacement 
was negatively correlated with both histopathological score 
(r = −0.70, p = < 0.001) and ADAM 8 expression in tissues of 
the back (r = −0.69, p <  0.001), and ADAM 8 was positively 
correlated with the histopathological score (r = 0.77, p < 0.001) 
(Figure 7).
Ex Vivo stretching experiments
In order to investigate the possible role of connective tissue 
fibroblasts in the response to stretching in the sclGvHD model, 
we conducted experiments in which connective tissue samples 
from control and sclGvHD mice are stretched ex vivo. We previ-
ously showed that connective tissue fibroblasts respond to tissue 
stretch ex vivo with cytoskeletal expansion accompanied by a 
drop in tissue tension (26) and that this fibroblast response is 
impaired in cross-linked collagen gels (27). We hypothesized 
that loss of fibroblast responsiveness to stretching may contrib-
ute to increased tissue stiffness in sclGvHd, and that stretching 
in  vivo may help preserve fibroblast responsiveness as well as 
tissue mobility. We first tested whether fibroblast responsiveness 
to stretching ex vivo is impaired in sclGvHD compared with 
controls. We measured fibroblast cross sectional area in tissue 
explants stretched versus non-stretched ex vivo from four groups 
of mice: control week 2, sclGvHD week 2, control week 4, and 
sclGvHD week 4 (Figure 8). We found that, at week 2, fibroblasts 
in explants from control and Scl GvHD responded similarly 
to ex vivo stretching (main effect of ex vivo stretch p < 0.001). 
However, at week 4, fibroblast expansion was reduced in explants 
from sclGvHD mice compared with controls (group by stretch 
interaction p  <  0.01) (Figure  9A). We then tested whether 
in  vivo stretching for 10  min/day in  vivo would prevent the 
FigUre 8 | Fibroblast cytoskeletal response to tissue stretch ex vivo. 
Tissue explants from Control and sclerodermatous graft-versus-host disease 
mice were excised immediately after euthanasia at week 2 or week 4, then 
stretched (S) versus non-stretched ex vivo for 2 h, followed by fixation and 
staining with phalloidin for measurement of cell body cross-sectional area 
(outlined as described in Section “Materials and Methods”).
FigUre 7 | relationship of relative tissue displacement, histological score, and aDaM8 mrna expression. Spearman’s correlation coefficients were 
r = −0.70, p ≤ 0.001 (a), r = −0.69, p < 0.001 (B), and r = 0.77, p < 0.001 (c).
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loss of fibroblast responsiveness ex vivo at week 4 and found no 
significant difference between mice that were stretched versus 
non-stretched in  vivo (Figure  9B). Thus, while cytoskeletal 
expansion and remodeling of connective tissue fibroblasts is 
clearly impaired in sclGvHD, this response was not improved by 
in vivo stretching. This suggests that fibroblast-mediated tissue 
relaxation is not part of the mechanism underlying the beneficial 
effect of stretching.
DiscUssiOn
In this study, we show that in vivo ultrasound is a valuable tech-
nique to monitor skin thickness and subcutaneous tissue mobil-
ity in the murine sclGvHD model. In addition, daily stretching 
produced a measurable beneficial effect since it reduced skin 
thickness and improved mobility during the fibrotic phase 
of the model (week  3). However, we found no differences in 
weight loss, clinical and histological scores between stretch and 
no stretch groups. A possible interpretation for these results is 
that our ultrasound findings were unrelated to any meaningful 
clinical improvement. On the other hand, it is also possible that 
ultrasound measurements are more sensitive than clinical and 
histological scores in following the course of the disease, since 
a marked increase in skin thickness in the sclGvHD mice was 
detectable with ultrasound at week 2 in the absence of clinical 
symptoms. This may be because the clinical score focuses on 
alopecia (and marginally periorbital swelling) which is more 
externally visible than skin swelling. Furthermore, clinicial 
scores do not reflect lack of tissue mobility which is one of 
the main sources of impairment in SSc. Even though clinical 
and histological scores were not different between stretch and 
no stretch groups, the correlation between skin mobility and 
histological scores suggests that skin mobility measured with 
ultrasound may be a useful and sensitive non-invasive marker 
in this model.
The mechanisms underlying any beneficial effect of stretch-
ing on skin thickness and mobility are at present unclear. 
Stretching reduced mRNA expression of CCL2 which is an 
important inflammatory mediator associated with the sclGvHD 
model (13, 14). The lack of accompanying reduction in clini-
cal symptoms stands in contrast to a previous study using this 
model in which treatment with CCL2 antibodies completely 
prevented the development of clinical and tissue pathology 
(13). However, CCL2 antibodies were administered systemi-
cally beginning immediately after cell transfer while, in our 
study, we only saw stretch-induced reduction of CCL2 at week 
4 and not at the peak of inflammation (week 2). It is, therefore, 
possible that reduction in CCL2 by stretching was not sufficient 
in magnitude or occurred too late to have a significant impact 
on the inflammatory process. Furthermore, we did not observe 
any reduction of inflammatory genes at week 2, suggesting that 
the reduced skin thickness and increased mobility observed at 
week 3 was not due to an early interruption of the inflammatory 
cascade.
Another possibility is that the effect of stretching is not pri-
marily anti-inflammatory, but rather is mechanical in nature. 
Reduced shear plane mobility of subcutaneous connective 
tissue can result from a number of interrelated factors, includ-
ing adhesions between tissue layers and increased connective 
tissue matrix stiffness due to increased collagen deposition 
and cross linking. We found no significant reduction in 
FigUre 9 | Ex vivo stretching experiments. (a): Connective tissue explants from control and sclerodermatous graft-versus-host disease (sclGvHD) mice were 
stretched (S) versus not stretched for 2 h ex vivo, then fixed and stained for measurement of fibroblast cross-sectional area as shown in Figure 8. Fibroblast 
response to ex vivo tissue stretch was reduced in sclGvHD mice that were euthanized at week 4 but not week 2, compared with controls. (B): In sclGvHD mice, 
daily in vivo stretching did not result in an increased fibroblast responsiveness to ex vivo stretching at week 4.
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TGF-β, TIMP-1, or MMP-12 with stretching, suggesting that 
stretching did not directly impact fibrotic matrix remodeling. 
We also found no improvement of fibroblast responsiveness to 
tissue stretch ex vivo in sclGvHD mice that had been stretched 
in  vivo, suggesting that tissue stiffness remained higher than 
in controls in both stretched and NS sclGvHD mice at week 4. 
This is consistent with our ultrasound findings showing further 
reduction in tissue mobility from week 3 to week 4 in both 
sclGvHD groups compared with controls. On the other hand, 
although in  vivo stretching did not fully reverse the pathol-
ogy, the reduction of ADAM8 mRNA expression in stretched 
mice and positive correlation of ADAM8, tissue mobility, and 
histological scores suggests a role for cell–matrix interactions 
in the effect of stretching, since matricellular proteins of the 
ADAM family have been implicated in mechanical signaling as 
well as inflammation (28, 29). Further studies will be needed 
to specifically examine the contribution of extracellular matrix 
stiffness and cell–matrix interactions to the effects of in vivo 
stretching.
Although mechanisms are at this point unclear, it is impor-
tant to note that the observed effects of stretching occurred in 
the absence of any other treatment. The implication of these pre-
clinical findings is that a systematic investigation of stretching as 
a therapeutic modality is warranted in patients with SSc. This is 
particularly important in light of a recent report that only 10% 
of SSc patients received physical/occupational therapy and that 
a frequent complaint from patients is that physical therapists 
are often reluctant to treat patients with SSc (6). The magni-
tude of improvement in tissue mobility (25%) observed in our 
study was comparable to improvements in range of motion of 
joints and other tissues that are considered clinically significant 
in other conditions (30), as well as the magnitude of clinical 
improvement typically found with commonly prescribed phar-
macological treatments in patients with diffuse sclerodermatous 
skin involvement (31, 32). Although the presence of deep tissue 
“friction rubs” has been reported as a clinical sign associated 
with poor prognosis and was suggested as a routine part of the 
rheumatologic physical examination (33), there are currently no 
established methods to quantify the involvement of deep tis-
sues. Dynamic ultrasound imaging has been successfully used 
in humans to measure the mobility of connective tissues (19), 
but so far this technique has not been applied to scleroderma. 
Thus, a next step in the translation of our current results to 
humans would be the development and validation of a clinical 
protocol using dynamic ultrasound to first follow the course of 
the disease, and then quantify the effects of treatments, includ-
ing stretching.
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